{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:50Z","timestamp":1791396110142,"version":"4.3.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2837,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011313","name":"Tokyo Biochemical Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011313","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.exphem.2014.03.010","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T06:32:12Z","timestamp":1400567532000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples"],"prefix":"10.1016","volume":"42","author":[{"given":"Masataka","family":"Hosoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiki","family":"Kumano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kamikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Nakauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.03.010_bib1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2014.03.010_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/bies.201100071","article-title":"Human pluripotent stem cells for disease modelling and drug screening","volume":"34","author":"Maury","year":"2012","journal-title":"Bioessays"},{"key":"10.1016\/j.exphem.2014.03.010_bib3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.03.010_bib5","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib6","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.03.010_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2006.06302.x","article-title":"Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens","volume":"135","author":"Merup","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.03.010_bib9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.exphem.2006.07.004","article-title":"Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia","volume":"34","author":"Wang","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2014.03.010_bib10","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.03.010_bib12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.20439","article-title":"Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis","volume":"81","author":"Harrison","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.03.010_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3109\/10428194.2012.722218","article-title":"Synergism between fibronectin and transforming growth factor-beta1 in the production of substance P in monocytes of patients with myelofibrosis","volume":"54","author":"Chang","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2014.03.010_bib15","doi-asserted-by":"crossref","first-page":"e21015","DOI":"10.1371\/journal.pone.0021015","article-title":"In\u00a0vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes","volume":"6","author":"Balduini","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.03.010_bib16","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2014.03.010_bib17","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1182\/blood-2007-10-117622","article-title":"Generation of functional platelets from human embryonic stem cells in\u00a0vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors","volume":"111","author":"Takayama","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1084\/jem.20100844","article-title":"Transient activation of c-MYC expression is critical for efficient platelet generation from\u00a0human induced pluripotent stem cells","volume":"207","author":"Takayama","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2014.03.010_bib19","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1182\/blood-2009-04-217406","article-title":"Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders","volume":"114","author":"Ye","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib20","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1182\/blood-2011-07-367441","article-title":"Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples","volume":"119","author":"Kumano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/srep00592","article-title":"Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells","volume":"2","author":"Mahalingam","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2014.03.010_bib22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2009-02-203695","article-title":"Definitive proof for direct reprogramming of hematopoietic cells to pluripotency","volume":"114","author":"Okabe","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/09553000802641136","article-title":"Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8","volume":"85","author":"Kuhlmann","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.exphem.2014.03.010_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","author":"Le Bousse-Kerdiles","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2014.03.010_bib25","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.010_bib26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:31:35Z","timestamp":1759566695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0301472X14001957"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.03.010","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}